TRAV1-2

Across TCGA pan-cancer cohorts, TRAV1-2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated TRAV1-2 data layer compared with 2 for mutation status.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TRAV1-2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated TRAV1-2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and HNSC show a favorable association.

SKCM, HNSC, and UCEC are the cancer types where TRAV1-2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.431	0.278	<.001	107	view →
HNSC	DFS	Tertile	IV	0.748	0.557	.001	77	view →
UCEC	OS	Tertile	All	0.749	0.585	.005	72	view →
BRCA	DFS	Median	All	0.596	0.471	<.001	66	view →
OV	DFS	Tertile	III,IV	0.199	0.118	.003	58	view →
LGG	OS	Tertile	All	0.682	0.844	<.001	42	view →
LIHC	DFS	Tertile	All	0.671	0.459	.001	33	view →
UVM	DFS	Quartile	All	0.455	0.827	.001	31	view →
KIRC	DFS	Tertile	II,III,IV	0.592	0.423	.009	21	view →
BLCA	DFS	Tertile	III,IV	0.366	0.167	.008	15	view →
ESCA	OS	Median	All	0.617	1.000	.009	13	view →
KICH	OS	Quartile	II,III,IV	0.834	1.000	.016	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

TRAV1-2–SKCM (OS)

Open the SKCM breakdown →